Martin F. Schacker
Chief Executive Officer at Tetragenex Pharmaceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Abel | M | 79 |
Tetragenex Pharmaceuticals, Inc.
 Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 30 years |
| Aaron S. Cohen | M | 87 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 23 years |
| William T. Comer | M | 85 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 23 years |
| Bruce J. Bergman | M | 76 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 30 years |
| Alf E. F. Akerman | M | 58 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 25 years |
| Kenneth Cartwright | M | 86 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 35 years |
| Robert Peter Budetti | M | 79 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 25 years |
| Richard J. Ablin | M | - |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 33 years |
| Joseph J. Hlavka | M | - |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 31 years |
| Gabriela Nicolau | M | - |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 29 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Neil Martucci | M | 49 |
M.S. Farrell & Co., Inc.
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 17 years |
| Thomas Anthony Gallo | M | 62 |
M.S. Farrell & Co., Inc.
| 10 years |
| Leonard John Amoruso | M | 58 |
Hofstra University
| 7 years |
| Dov Elefant | M | 56 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 8 years |
| Roger Norman Freeman | M | 82 |
Lehman Brothers Holdings Plc
 Lehman Brothers Holdings Plc Investment Banks/BrokersFinance Lehman Brothers Holdings Plc provides finance and treasury management services. The company is headquartered in London, UK. | 14 years |
| Philip J. Shapiro | M | 71 |
Hofstra University
| 3 years |
| Peter L. Janoff | M | 67 |
Hofstra University
| 3 years |
| Vince Tattersall | M | - |
Lehman Brothers Holdings Plc
Lehman Brothers Holdings Plc Investment Banks/BrokersFinance Lehman Brothers Holdings Plc provides finance and treasury management services. The company is headquartered in London, UK. | 7 years |
| Evan Rudowski | M | 60 |
Hofstra University
| 4 years |
| Romano Tio | M | 64 |
Hofstra University
| 4 years |
| William H. Dailey | M | - |
Hofstra University
| 4 years |
| George Germano | M | - |
Hofstra University
| 4 years |
| Sayed Deyab | M | 72 |
Hofstra University
| 2 years |
| Rich Familetti | M | 60 |
Hofstra University
| 4 years |
| Marc Alpert | M | 61 |
Hofstra University
| 4 years |
| Thomas Tesauro | M | - |
Hofstra University
| 4 years |
| Kevin F. Higgins | M | - |
Hofstra University
| 4 years |
| Daisy Fernandez Seebach | F | - |
Hofstra University
| 3 years |
| Peter Mayo | M | - |
Hofstra University
| 4 years |
| Larry Goldsmith | M | - |
Hofstra University
| 4 years |
| Robert F. Carlin | M | - |
Hofstra University
| 3 years |
| Andrew M. Silverman | M | - |
Hofstra University
| 4 years |
| James Edward Keenan | M | 69 |
Hofstra University
| 4 years |
| Richard Serio | M | - |
Hofstra University
| 4 years |
| Stephen B. Kass | M | 61 |
Hofstra University
| 4 years |
| George D. Fischer | M | - |
Hofstra University
| 2 years |
| Norman W. Feckl | M | - |
Hofstra University
| 4 years |
| Yemi Oshodi | M | - |
Hofstra University
| 4 years |
| James Nuzzo | M | 62 |
Hofstra University
| 4 years |
| Dino F. Giannatos | M | 67 |
Hofstra University
| 4 years |
| David Brian Newman | M | 64 |
Hofstra University
| 4 years |
| Ken Kamen | M | - |
Hofstra University
| 4 years |
| Steve R. Brown | M | - |
Hofstra University
| 2 years |
| Renee Reynolds | F | - |
Hofstra University
| 4 years |
| Edward Kalikow | M | - |
Hofstra University
| 3 years |
| Peter W. Shafran | M | 66 |
Hofstra University
| 3 years |
| Adam R. Kolodny | M | 61 |
Hofstra University
| 4 years |
| Jay Kushner | M | 68 |
Hofstra University
| 3 years |
| Mitchell S. Segal | M | 63 |
Hofstra University
| 3 years |
| Randy Scott Zelin | M | 59 |
Hofstra University
| 4 years |
| Deborah Bloom | F | - |
Hofstra University
| 2 years |
| Annie Erner | F | - |
Hofstra University
| 2 years |
| Ira Seth Lederman | M | 69 |
Hofstra University
| 3 years |
| John P. Feighner | M | - |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 7 years |
| Andrew Mark Boas | M | 69 |
Hofstra University
| 3 years |
| Pat Carroll | M | 60 |
Hofstra University
| 4 years |
| Mark Schwartz | M | - |
Hofstra University
| 4 years |
| John Phelps Ingersoll | M | 93 |
Lehman Brothers Holdings Plc
Lehman Brothers Holdings Plc Investment Banks/BrokersFinance Lehman Brothers Holdings Plc provides finance and treasury management services. The company is headquartered in London, UK. | 5 years |
| Sean McGowan | M | - |
Hofstra University
| 4 years |
| Douglas Maine | M | 75 |
Hofstra University
| 3 years |
| Victor J. Brodsky | M | 66 |
Hofstra University
| 4 years |
| Mark R. Basile | M | 65 |
Hofstra University
| 4 years |
| Thomas Procelli | M | 69 |
Hofstra University
| 2 years |
| David K. Steel | M | 66 |
Lehman Brothers Holdings Plc
Lehman Brothers Holdings Plc Investment Banks/BrokersFinance Lehman Brothers Holdings Plc provides finance and treasury management services. The company is headquartered in London, UK. | - |
| Victor D. Russo | M | - |
Hofstra University
| 4 years |
| Stephen Bondi | M | - |
Hofstra University
| 4 years |
| Don J. Hofmann | M | - |
Hofstra University
| 4 years |
| Vincent J. McGill | M | 69 |
Hofstra University
| 3 years |
| Peter Strebel | M | - |
Hofstra University
| 4 years |
| Jeffrey Weiner | M | 66 |
Hofstra University
| 4 years |
| Richard Perrotti | M | - |
Hofstra University
| 4 years |
| Yair Talmor | M | - |
Hofstra University
| 2 years |
| J. Todd Morley | M | - |
Lehman Brothers Holdings Plc
Lehman Brothers Holdings Plc Investment Banks/BrokersFinance Lehman Brothers Holdings Plc provides finance and treasury management services. The company is headquartered in London, UK. | 3 years |
| Fred Mannheimer | M | - |
Hofstra University
| 6 years |
| Douglas Brodman | M | - |
Hofstra University
| 2 years |
| Nigel J. B. Lovett | M | 78 |
Lehman Brothers Holdings Plc
Lehman Brothers Holdings Plc Investment Banks/BrokersFinance Lehman Brothers Holdings Plc provides finance and treasury management services. The company is headquartered in London, UK. | 12 years |
| James Tracy Colby | M | - |
Hofstra University
| 2 years |
| Mark L. DiMarsico | M | - |
Hofstra University
| 4 years |
| Edward B. Vinson | M | - |
Hofstra University
| 3 years |
| Lisa Mumford | F | 60 |
Hofstra University
| 4 years |
| Michael Alicastro | M | - |
Hofstra University
| 4 years |
| Robert Edward Bies | M | 66 |
Hofstra University
| 2 years |
| Lawrence Chariton | M | 67 |
Hofstra University
| 4 years |
| Anthony M. Gallo | M | - |
Hofstra University
| 4 years |
| Warren Hirsch | M | 66 |
Hofstra University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 79 | 92.94% |
| United Kingdom | 6 | 7.06% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Martin F. Schacker
- Personal Network
